Full Text View
Tabular View
No Study Results Posted
Related Studies
Dichotic Listening as a Predictor of Medication Response in Depression
This study has been completed.
Study NCT00296725   Information provided by New York State Psychiatric Institute
First Received: February 24, 2006   Last Updated: January 14, 2008   History of Changes

February 24, 2006
January 14, 2008
April 1994
 
  • Hamilton Depression Scale (HAM-D) [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Fuse Words Test [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Nonsense Syllables Test [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Complex Tones Test [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Hamilton Depression Scale (HAM-D)
  • Fuse Words Test
  • Nonsense Syllables Test
  • Complex Tones Test
Complete list of historical versions of study NCT00296725 on ClinicalTrials.gov Archive Site
  • Clinical Global Impression Scale (CGI) [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Atypical Depression Diagnostic Scale (ADDS) [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Deragotis Sexual Performance Scale [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Snaith-Hamilton Pleasure Scale [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Spielberger State/Trait Anxiety Scale [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
  • Clinical Global Impression Scale (CGI)
  • Atypical Depression Diagnostic Scale (ADDS)
  • Derogotis Sexual Performance Scale
  • Snaith-Hamilton Pleasure Scale
  • Spielberger State/Trait Anxiety Scale
 
Dichotic Listening as a Predictor of Medication Response in Depression
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression

Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine and Placebo) until remitted, to see whether test results predict specific outcomes.

Preliminary data suggest that depressed patients with increased left hemispheric laterality of perceptual processing are unlikely to improve during six weeks' treatment with placebo, while being very responsive to either imipramine or fluoxetine. Depressed patients who do not show evidence of poor right hemispheric functioning respond significantly more often to placebo than those with poor right hemispheric functioning, and do not show an advantage of drug over placebo. 100 depressed patients will be tested with verbal and nonverbal dichotic tests, and then treated sequentially with Placebo, Fluoxetine and Imipramine until remitted. Preferential hemisphere for auditory processing will be correlated with treatment outcome.

Phase IV
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study
  • Major Depression
  • Dysthymia
  • Depressive Disorder NOS
  • Drug: Fluoxetine
  • Drug: Imipramine
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
130
 
 

Inclusion Criteria:

  • Ages between 18-65
  • Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS

Exclusion Criteria:

  • Known hearing impairment
  • Active suicidal ideation (history of suicide attempts will be evaluated on a case by case basis)
  • HAMD > 20
  • Current (past six months) alcohol and/or drug abuse or dependence
  • Medical condition likely to require intervention contraindicated with study medication (e.g., known arrhythmia likely to be exacerbated by Imipramine)
  • Bipolar I
  • Psychosis
  • If currently taking antidepressants or mood stabilizers, cannot be off psychotropic medication for 7 weeks (10 weeks for Prozac) or felt to require other psychiatric medication (other than occasional sleep or Anxiety medication)
  • Premenopausal women not using known effective birth control
  • Not currently depressed (whether considered due to current treatment or not)
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00296725
Jonathon W. Stewart, M.D., New York State Psychiatric Institute
IRB4217R, continuation of IRB3112;, became IRB5294R.
New York State Psychiatric Institute
 
Principal Investigator: Jonathan W. Stewart, MD. New York State Psychiatric Institute - Columbia University Department of Psychiatry
New York State Psychiatric Institute
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP